Earnings summaries and quarterly performance for SLRN.
Executive leadership at SLRN.
Board of directors at SLRN.
Research analysts who have asked questions during SLRN earnings calls.
Samantha Semenkow
Citigroup Inc.
2 questions for SLRN
Also covers: ALLO, ARGX, BEAM +7 more
Vikram Purohit
Morgan Stanley
2 questions for SLRN
Also covers: ABSI, ARGX, ARQT +11 more
Akash Tewari
Jefferies
1 question for SLRN
Also covers: ALKS, APLS, ARGX +15 more
Emily Bodnar
H.C. Wainwright & Co.
1 question for SLRN
Also covers: AGEN, AGIO, ATOS +6 more
Phebe
Jefferies
1 question for SLRN
Yasmeen Rahimi
Piper Sandler & Co.
1 question for SLRN
Also covers: ALT, ARCT, CRNX +12 more
Recent press releases and 8-K filings for SLRN.
Alumis (formerly ACELYRIN, Inc.) Details Financial Position and Key Clinical Milestones
SLRN
M&A
New Projects/Investments
- Alumis (formerly ACELYRIN, Inc.) had $486.3 million in cash as of June 30, 2025, providing a runway into 2027 beyond multiple expected clinical data readouts.
- The company anticipates topline data from Phase 3 ONWARD trials for envudeucitinib in moderate-to-severe plaque psoriasis in early 1Q 2026, and topline data from Phase 2b LUMUS trial in systemic lupus erythematosus in 3Q 2026.
- Alumis expects to initiate a Phase 2 clinical trial for A-005 in Multiple Sclerosis in 1H 2026 and anticipates Phase 1 clinical data for a third clinical candidate in 2026.
- The Alumis / ACELYRIN merger closed in 2Q 2025.
Aug 13, 2025, 8:00 PM
ACELYRIN Completes Merger and Initiates Delisting Process
SLRN
M&A
Delisting/Listing Issues
- On May 21, 2025, ACELYRIN completed its merger with Merger Sub, becoming a wholly owned subsidiary of Alumis. Under the transaction, each share of ACELYRIN common stock was converted into 0.4814 shares of Alumis common stock plus cash for any fractional shares.
- The company terminated its 2023 Employee Stock Purchase Plan and requested Nasdaq suspend trading and initiate delisting of its common stock as part of its corporate restructuring.
May 21, 2025, 12:00 AM
ACELYRIN, Inc. Approves Merger and Adjournment Proposals
SLRN
M&A
Proxy Vote Outcomes
- ACELYRIN, Inc. held a virtual special meeting on May 13, 2025, where stockholders voted on key proposals related to its merger with Alumis Inc. and associated adjournment measures.
- The merger proposal was approved with 52,943,588 votes for against 41,376,937 votes against, and the adjournment proposal received 47,828,119 votes for, with a planned closing on May 21, 2025.
May 19, 2025, 12:00 AM
ACELYRIN Announces Revised Merger Terms with Alumis
SLRN
M&A
- ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock per share, resulting in an approximate 48% ownership in the combined company, compared to Alumis’ 52% (referenced in ).
- The investor presentation highlights potential value upside from key upcoming milestones, including a Phase 3 data readout in Q1 2026, with pro forma equity values projected between $6.90 and $8.96 per ACELYRIN share (referenced in ).
- The merger is structured to significantly extend financial runway, supported by a pro forma cash position of approximately $737 million as of 4Q24, ensuring operational funding into 2027 (referenced in ).
Apr 21, 2025, 12:00 AM
ACELYRIN Adopts Limited-Duration Rights Plan
SLRN
Takeover Bid
- ACELYRIN, Inc. has adopted a limited-duration stockholder rights plan effective immediately, which will expire on March 12, 2026.
- The plan issues one right per share of common stock as of the March 24, 2025 record date, allowing holders to purchase additional shares if an acquiring party exceeds a 10% (or 20% for Schedule 13G reporters) threshold.
- This action is a defensive measure in response to Tang Capital Partners' accumulation of 8.8% of the company’s outstanding stock, aiming to protect shareholder value.
Mar 13, 2025, 12:00 AM
Quarterly earnings call transcripts for SLRN.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more
Let Fintool AI Agent track SLRN's earnings for you
Get instant analysis when filings drop